Dendreon National Sales Conference was held in Las Vegas on July 19, USA local time, to review sales performance of the first half of 2017 and to make sales plan for the second half. Attendees of this conference included Xu Fang, Senior Vice President of Sanpower Biomedicine and Chairman of Dendreon, Jim Caggiano, Dendreon CEO, Matt Kemp, Dendreon CCO, Christina Yi, Dendreon COO and over 100 sales representatives from 5 sales areas in the U.S.

2017 is a special year for Dendreon. In January, Chinese private company Sanpower Group signed a share purchase agreement with Valeant, the former parent company of Dendreon. On June 29, the equity delivery was officially completed. Dendreon has officially transformed from a business department of Valeant to an affiliate of Sanpower Group, an independent operation entity. In the first half of this year, its core product, Provenge, the first and only FDA-approved cellular immunotherapy for prostate cancer, experienced a great raise of sales due to the change of market strategies and channels. The sales of the first half year has reached a record performance with a rise of 10% year on year. The inspiring sales performance and expectation for the new parent company inspired all sales staff at this conference.   

It was the first sales conference after Dendreon had been acquired by Sanpower Group. At this conference, Mr. Yuan Yafei, Chairman of Sanpower Group, delivered a speech via video. He said that as the equity delivery was completed, Dendreon has become a critical link in the ecosystem of Sanpower Group. It is Dendreon’s top priority to maintain constant profitability and achieve long-term development. Sanpower Group has made a comprehensive strategic plan to promote the development of Dendreon to a new level. The top task of the future strategy is to keep and inspire the management team and core talents of Dendreon. Sanpower believes that the local management team knows local situations the best, which is also a belief that Sanpower Group always holds to when it deals with overseas M&As. 

Mr. Yuan Yafei also mentioned his expectation of Dendreon management team that, while maintaining the development momentum in US market, the team should set the goal of the next stage as to enter the international market, preparing Provenge for entering Chinese and Southeast Asian markets.

Jim Caggiano, Dendreon CEO said that, in the process of the acquisition, some concerned whether the acquisition could be smoothly carried out. Now the successful delivery has shattered these worries and suspicion. He was glad that with the help of Sanpower, Dendreon can operate as an independent company again. He believed that Sanpower Group can help Dendreon enter global market and achieve a better development.  

Xu Fang, Senior Vice President of Sanpower Biomedicine has 25 years of experience in medicine and healthcare industry. After the acquisition, she took the official position as the Chairman of Dendreon and was warmly received by Dendreon’s management team. At the sales conference, Xu Fang introduced the business development of Sanpower Group, the new parent company of Dendreon, in China, especially its layout in the medicine and healthcare sector. She also introduced the goal of the acquiring Dendreon and entering the Chinese market in the future. She said that Dendreon and Sanpower’s industries would produce synergistic effect. Xu Fang said that in the process of the acquisition of Dendreon, both teams cooperated well and constructively. Sanpower hoped to introduce Provenge to new markets to explore more development potential.